Microsoft word - resume - christopher neuman.doc
Toronto, Ontario 123-456-7890 firstname.lastname@example.org
Additional information and recomendations: www.linkedin.com/in/christopherneuman
PRESIDENT / CEO WITH 12 YEARS OF FULL P&L RESPONSIBILITY
Expert in: Marketing ~ Product Identification & Review ~ Start-Up & Turnaround Management
Entrepreneurial Marketing and Operations Management Executive
successful at leading midsize Pharmaceutical, Biotech and Medical Device
companies to grow in value, and be positioned for rapid expansion and/or acquisition by an industry leader or a Venture Capital firm. Business and
scientific understanding of the relationships between R&D, clinical trials, production, marketing and technology; with a track record of negotiating
contracts & licensing agreements, and evaluating offerings from pharma/biotech companies and the processes and finances needed to achieve
value enhancing deals. Level headed business strategist and team leader with a keen sense of purpose and urgency when faced with solving
diverse situational chal enges in marketing, plant operations and finance. Adept at establishing product development pipelines, new markets, and
operational excel ence within cultural y diverse environments. Able to translate conceptual models into specific growth strategies, and plan and
execute multi-faceted global business development campaigns designed to improve market share and gross revenue. Over twenty years of pro-
active Board of Director experience with commercial companies, not-for-profit institutions and industry associations. Key qualifications include:
♦Long and Short Term Corporate Vision & Strategic Planning
♦ Competitive Analysis & Innovative Go-To-Market Thought Leadership
♦Joint Ventures & Strategic Business Partnerships
♦ IPOs - Capital Markets - Venture Capital - Private Financing - M&As
♦ Financial Planning & Analysis and Ful P&L Management
♦ Investor, Stakeholder and Board of Directors Relations / Public Relations
♦ Cross-Border Trade & Finance Transactions
♦ Divestitures / Change Management / Turn Around Management
♦ Product Portfolio Acquisition and Marketing & Product Branding
♦ Cost Reduction/Containment & Revenue/Profit Optimization
♦ International Product Development & Direct Marketing
♦ Plant Management /Operations Re-engineering / Process Improvement
♦ Market Penetration & Pricing Strategies
♦ Negotiating/Bidding Hospital Contracts
Masters Business Administration in Marketing, Concordia University
Bachelor of Commerce in Management, Concordia University
Bachelor of Science in Chemistry, SGWU University
Numerous Seminar Courses Related to Senior Management
Turned around ALZA Canada - Baker Cummins, a company performing wel below expectations, and achieved 650% growth in less than 4 years. This was achieved by re-defining the overal business strategy, divesting the legacy OTC low margin dermatology products, and investing in the urology based Rx products; the main urology product became the Gold Standard
in its indication. Also established effective market planning and marketing efforts, novel direct to the consumer educational programs (Rx product) along with professional accounting, forecasting and supply chain management systems. Established professional business systems within complete company.
Gained FDA, TPP, and EU approval for Pheromone Sciences Corp. to market a new medical device by rebuilding a clinical trial that would not have passed rigorous critical evaluation. Met personal y with leading experts to better understand the medical conditions, measurements and processes, and created new clinical study process with al record keeping documents as per FDA standards; recruited experts in fertility to do research and hired Duke University Clinical Research Institute to conduct statistical analysis.
Provided a new client with marketing assessments of several potential product acquisitions including potential sales revenues given the
warranted investment in pre and post marketing investments; analysis included competitor assessment, strengths, weakness and likely competitive responses. Recommendation on 8 projects was to not acquire the product, which validated management’s opinion; and for a major Rx pain product the forecast was within a few percentage points of actual performance after 24 months.
Consulted for a pharmaceutical client to determine the effects of a price increase of a prescription product in a control ed marketplace like
Canada. After careful y evaluating and assessing the benefits / risks of a substantial price increase, recommended a 95.5% price increase based upon patent status, competitive pricing, formulary restrictions, usage patterns, consumer behavior with unanimous corporate buy-in and no more than the anticipated operational and marketing issues to develop actions to deal with.
Organized new prescription business in Canada with goal to extend business to USA within 24 months. Prepared al materials required for
$25 mil ion IPO and built business plan designed to hit C$300M in 5 years. Evaluated and created revenue and market potential forecast for over 200 products and selected 54 for Canadian launch over 4 years time frame. Recruited exemplary Board of Directors, hired corporate lawyers, trademark lawyers, auditors etc.
C. NEUMAN & ASSOCIATES, Toronto, Ontario
2006 to Present
MANAGING DIRECTOR / LIFE SCIENCES BUSINESS CONSULTING SPECIALIST
Obtained projects in consortium with In Initiative Inc. and Pangaea Customized Consulting (Canada’s leading Pharmaceutical/Biotech consulting firms), Dexel Marketing Inc., and through referrals from personal contacts. Provide comprehensive business, sales & marketing and operations expertise focusing on multiple healthcare clients Rx, OTC, Natural Health Products, and medical devices.
Long Term Consulting projects focused on:
Establishing new companies in Canada, including the creation of detailed business plans with supporting budgets.
Providing resource deployment studies for clients; successful y launching several corporate re-organizations / re-structures
Strategic & Corporate planning, new product valuation, acquisition or divestment advice; managing new product and market assessments and conducting Market Access Projects / Pricing Evaluations.
GENEPHARM CANADA, Toronto, Ontario (Canadian subsidiary of European specialty, generic & Brand Pharma Co)
2004 to 2006
PRESIDENT & CEO / DIRECTOR & BOARD SECRETARY
Brought on board to start-up new North American operations with total responsibility for P&L, strategic planning, marketing & sales, operations management, business development, TSX & investor relations, finance and regulatory affairs.
Established strategic planning process and execution of regulatory and marketing activities in support of the operations plan to submit 54+
drug product dossiers to Health Canada. Business plan was to become $300+ mil ion business by 2010 and lead the business expansion into the USA.
Organized al aspects of a new prescription specialty drug business as a Canadian spin off from the European based operational company.
Conducted al activities required to launch a $25 mil ion (Canadian) IPO and a TSX listing, including the recruitment and engagement of
Board Members, key corporate lawyers, auditors, investment bankers and senior staff recruitment, writing of prospectus and other support documents related to the financing and operating the business (business plan, market research reports, market assessments).
PHEROMONE SCIENCES CORPORATION, Toronto, Ontario
2000 to 2004
PRESIDENT & CHIEF EXECUTIVE OFFICER / DIRECTOR & BOARD SECRETARY
Maintained ful accountability for the global operations, P&L, strategic planning, operations/financial management, business development, advocacy development, investor relations, clinical research, regulatory affairs, marketing activities, internet sales strategy and fund raising for this TSX listed Pharmaceutical & Medical Device R&D company ),
Achieved FDA, CE Mark (Europe) and Health Canada approval for key product: the fertility prediction medical device, the Fertility
Monitor™ and created R&D programs to expand technology for use in the animal health marketplace. The Fertility Monitor was approved after clinical trials were executed at Thomas Jefferson University Hospital and Duke University Hospital. Duke University Clinical research Institute was hired to conduct the statistical analysis of the trial results.
Reduced operating expenses by 35%, created royalty flow of 5% of al sales for technology in the Far East (out-license), led 3 rounds of
private equity financing and sold technology to a Florida based company with substantial ROI.
ALZA CANADA / BAKER CUMMINS INC., Markham, Ontario
1995 to 2000
PRESIDENT & GENERAL MANAGER
Successful y drove business strategy, sales & marketing and product & business development for a line of dermatology and urology products, and was instrumental in establishing productive business relationships with physicians and consumers with stel ar results in terms of revenue and brand recognition.
Propel ed this Canadian subsidiary of an international pharmaceutical company from $2 mil ion to $25 mil ion revenue with corresponding
improvement in profit margins achieved through aggressive market expansion and market penetration strategies.
Acquired 8 urology oriented products directed at the established key customer groups; identified several products in company’s American
operation that would be additive to Canadian operation; and divested dermatology line of products which no longer fit the organization.
Initiated clinical research program for lead product to penetrate new areas of usage for product with results surpassing expectations.
Increased sales force productivity by 25%; and realigned business operations while introducing technology to improve overal productivity.
Also instituted strict financial controls and supply chain management features to enhance the company’s competitive edge.
BOOTS PHARMACEUTICALS, Toronto, Ontario
1993 to 1995
DIRECTOR OF MARKETING & BUSINESS DEVELOPMENT
Directed and led al marketing and business development activities for the Canadian division of this UK based multinational Pharma Co; in addition to business development responsibilities (part-time) at the Chicago based USA office for a period of 9 months.
Grew total company revenues by 60% through the implementation of new marketing and business development strategies, team building,
mentoring and innovative product awareness & sales training measures.
Grew Synthroid sales by 20% and market share +22% by repositioning the brand and aggressively marketing it in the face of direct head
Contributed to international marketing efforts of company by playing a key membership role on cross-functional international product
development and marketing teams in the cardiovascular and CNS product categories.
PHARMASCIENCE INC., Montréal, Québec
1991 to 1993
DIRECTOR OF SALES & MARKETING
Successful y directed al marketing, sales and distribution activities for al divisions at this national brand, generic and diagnostic Pharma Co (Brand Rx, Generic OTC. Al ergy, Surgery, Fertility); and led a team of 120 employee in marketing, sales, customer service, order processing and telemarketing.
Grew sales by 44%, achieved by implementing innovative sales & marketing and team building strategies.
Established market planning system and process for al business plans covering 500+ SKUs.
Spearheaded the growth in professionalism of the sales and marketing team by bringing sophisticated big pharma planning and training
Launched several new products in branded and multi-sourced product markets each year.
MARION MERRELL DOW INC., Laval, Quebec
1983 to 1991
DIRECTOR OF MARKETING (1987-1991) / GROUP PRODUCT MANAGER (1985-1987) / PRODUCT MANAGER (1983-1985)
Directed al marketing and business development activities for al divisions of this multinational pharmaceutical company now known as Aventis. Responsibility included project management for al product launch activities, management of CME activities in support of the products, development of staff. Represented the company at industry association functions. Specific skil s utilized include strategic planning, budget creation and control, creation of in depth, novel and creative business plans and staff motivational plans.
Accelerated revenue from $1 mil ion to $25 mil ion for Sulcrate by re-positioning the product competitively.
Launched major new product for hypertension and angina, leading company to top 5 industry sales position along with several product line
Directed a very substantial advertising and promotional campaign with a correspondingly large sales budget, managed marketing
department of 28 people (brands in cardiovascular, wound care, endocrinology, gastrointestinal and general medicine products).
Became leader within International Marketing community for our products
Improved branding recognition and sales for a basket of OTC and prescription products in multiple therapeutic classes through creative
Established and managed telemarketing sales department.
CURRENT BOARD MEMBERSHIPS & PROFFESIONAL AFFILIATIONS
Toronto Central Community Care Access Centre – Director, Member Governance Committee – 2009 (a $180 mil ion agency with 500+ staff)
Myrex BioPharmaceuticals – Director 2008-2009
Canadian Food Safety Institute – Director 2008-2009
Toronto Biotech Initiative - Member since 2000
Canadian Healthcare Licensing Association - Founding Executive 1993 – 1996 and 2004 – present
University Lecturer: Concordia University: Marketing and Management, 1983 - 1993 / McGil University MBA Program: Marketing, 1987– 1993
AH Self-funded Pharmacy Formulary* (updated 1/2011) *maximum allowed towards deductible or paid by AH. Other medications will not be paid. Requests for additions to formulary can be made to Dr. Johnston. **Please note: prices are subject to change for any medication. Level 1 Generic Level 2 Generic & Name Brand Level 1 Generic Level 2 Generic & Name Brand Allergies
Odilien-Apotheke Tel. +49 (2403) 26830 Fax. +49 (2403) 839169 Onlineshop: www.apodil.de email: email@example.com Kompendium 2013/2014 Taschenapotheken Komplexmittel Einzelmittel Bachblüten Schüsslersalze Pflanzliche Arzneimittel Zubehör 1. Nosoden (herstellbar ab der angegebenen Potenz) C6 / D10 Folliculinum Nos. (Follikelhormon, synth.)Chron bakterie